Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

06/16/2026, 1:00 PM • GlobeNewswire

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and biotech financial leadership, including previous CFO roles at Cardiff Oncology and Cidara Therapeutics, where he led major pharmaceutical partnerships. His appointment is expected to support Kazia's advancement of its lead asset paxalisib across multiple cancer indications and pipeline development.

06/02/2026, 7:30 AM • Benzinga

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics announced the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate MSETC is designed to restore immune signaling in tumors resistant to immunotherapy. Kazia plans to advance the SETDB1 program alongside its PD-L1 degrader platform to IND readiness within 18 months at an estimated cost of $6 million, leveraging shared resources and expecting to qualify for Australian R&D tax incentives.

04/13/2026, 5:05 PM • Benzinga

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations and expanded biomarker analyses. Kazia also plans to provide the first update on its potential first-in-class PD-L1 protein degrader program.

01/08/2026, 9:00 AM • Benzinga

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response when treated with paxalisib combined with pembrolizumab and standard chemotherapy, showing a profound radiologic response in a highly aggressive cancer subtype.

11/18/2025, 4:15 PM • Benzinga

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Kazia Therapeutics plans to request an FDA meeting to discuss overall survival data for paxalisib, a potential treatment for glioblastoma, aiming to pursue conditional approval under the FDA's Project FrontRunner initiative.

10/27/2025, 7:15 AM • Benzinga

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics reported an 86% reduction in tumor burden for a metastatic triple-negative breast cancer patient using a combination of paxalisib, immunotherapy, and chemotherapy in an expanded-access case.

10/02/2025, 8:30 AM • Benzinga

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Kazia Therapeutics is participating in a three-year Australian Medical Research Future Fund project to develop an AI-enabled clinical decision-making platform for treating diffuse midline glioma (DMG), contributing its investigational drug paxalisib to optimize targeted therapies for pediatric brain cancers.

10/01/2025, 9:21 AM • Benzinga

Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight

The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.

09/09/2025, 1:00 PM • GlobeNewswire